



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

# 6  
10/24/02  
89  
RECEIVED  
OCT 22 2002  
TECH CENTER 1600/2900

In re application of

Docket No: Q67050

Hiroyuki HISAMICHI, et al.

Appln. No.: 10/009,276 ✓

Group Art Unit: 1625

Confirmation No.: 6088

Examiner: NOT YET ASSIGNED

Filed: December 10, 2001 ✓

For: NOVEL HETEROCYCLECARBOXAMIDE DERIVATIVE ✓

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

Applicants have provided herewith a copy of U.S. Patent 6,432,963 B1, issued August 13, 2002. This patent corresponds to the document WO 99/31073 which was identified in the IDS filed on December 10, 2001, but which is in a foreign language. Accordingly, the submission of this corresponding U.S. patent constitutes a concise statement of relevance for the foreign language document.

One copy of each of the listed documents is submitted herewith, along with a copy of the corresponding European Search Report, which cites three published PCT applications. However,

INFORMATION DISCLOSURE STATEMENT  
U.S. Appln. No.: 10/009,276

two of those three documents were submitted in the December 10, 2001 IDS, and therefore only WO 98/41512 is being filed concurrently herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date for an application other than a continued prosecution application (CPA) under §1.53(d); (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Mark Boland", followed by a checkmark.

Mark Boland  
Registration No. 32,197

SUGHRUE MION, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Date: October 21, 2002